Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer

• DOI: 10.1007/s12325-022-02086-5
• Publication Date: 2022-04-01T10:44:40Z
• Authors: Daniel Simmons; Stephanie V. Blank; Adam C. ElNaggar; Benjamin Chastek; Scott H. Bunner; Kimmie McLaurin
• Keywords: Health plan; Medicare Advantage

Ovarian cancer (OC) is one of the leading causes mortality among women in United States. With approval first-line maintenance therapies, patients with OC experienced prolonged progression-free survival. While literature addresses some costs associated OC, further research needed on progression that are potentially deferred or prevented by early maintenance. The objective this study was to capture health care resource utilization and advanced who never received poly(ADP ribose) polymerase (PARP) inhibitor We conducted a descriptive retrospective analysis treatment patterns consequences through several lines therapy (LOTs) using claims from commercial Medicare Advantage plan members States Optum Research Database between January 1, 2010, April 30, 2019. Patients were required have an index diagnosis (≥ 2 non-diagnostic claims). examined up 4 LOTs time treatments. A total 5498 met eligibility criteria. As number increased, median duration each line decreased 137 days LOT1 94 LOT4, also 245 0 days. Ambulatory visits major driver utilization, about 6 monthly during active treatment. mean for at least US$8588 (SD: $8533) before LOT2 increased $15,358 $21,460) after LOT2. Prolonging survival may provide opportunity delay prevent later treatment, financial toxicity felt patients, economic burden system progression. complex disease which > 70% diagnosed disease, variety options, including bevacizumab, PARP inhibitors, plus bevacizumab combination demonstrated improvements By delaying completion therapy, simultaneous decrease post-progression be seen. ovarian did not receive any their In receiving inhibitor, documented substantial usage beyond first (surgery and/or chemotherapy) cancer. These largely driven ambulatory visits. When these combined emergency department inpatient stays, high incurred both third-party payers need subsequent progressions